Idiopathic Pulmonary Fibrosis Market Analysis, Size, Share & Growth Forecast 2026–2034

Nintedanib INPULSIS 125 Versus 207 mL Annual FVC Decline Demonstrating 50 Percent Reduction in Lung Function Deterioration Rate Has Established the Antifibrotic Efficacy Standard That New IPF Drug Development Uses as the Benchmark Against Which Additional Benefit Must Be Demonstrated.Boehringer Ingelheim's nerandomilast demonstrated 19% reduction in FVC decline over 52 weeks versus placebo on top of background antifibrotic therapy in FIBRONEER-IPF, establishing that selective PDE4B inhibition provides additive antifibrotic benefit beyond nintedanib or pirfenidone monotherapy. The PDE4B selectivity over PDE4D reduces the gastrointestinal side effects of pan-PDE4 inhibitors like roflumilast while preserving the anti-inflammatory and antifibrotic effects of cyclic AMP elevation in lung fibroblasts and macrophages. Nerandomilast's add-on approval creates a combination antifibrotic regimen where two complementary mechanisms, TGF-β pathway inhibition through nintedanib or pirfenidone and PDE4B inhibition through nerandomilast, address different drivers of lung fibrosis progression simultaneously.

Nintedanib INBUILD Progressive Fibrosing ILD Indication Expansion Beyond IPF to CTD-ILD, Sarcoid Fibrosis, and Hypersensitivity Pneumonitis Has Extended the Antifibrotic Approach to the Progressive Fibrosing Lung Disease Category That Shares the TKI-Sensitive Fibrogenic Pathway.United Therapeutics's inhaled treprostinil demonstrated 30.5-metre improvement in 6-minute walk distance versus placebo in INCREASE in IPF-associated pulmonary hypertension, establishing the first approved therapy for a complication affecting approximately 30-50% of IPF patients that significantly worsens dyspnoea and exercise limitation beyond the underlying lung fibrosis. The inhaled delivery route targets the pulmonary vasculature directly with minimal systemic prostanoid effects including the headache, flushing, and jaw pain that limit parenteral prostacyclin use in IPF-PH patients. The INCREASE data has generated interest in extending inhaled prostanoid benefit to pulmonary hypertension associated with other interstitial lung diseases including connective tissue disease-ILD and hypersensitivity pneumonitis where PH complicates a substantial minority.

Antifibrotic IPF Lung Transplant Bridge Therapy Using Pirfenidone or Nintedanib to Slow Progression During the Transplant Wait Has Addressed the Listing Urgency Deterioration That Quickly Progressive IPF Creates for the Bilateral Lung Transplant Candidate.FibroGen's pamrevlumab anti-CTGF and United Therapeutics's GB1275 CD11b modulator represent additional antifibrotic mechanisms advancing through Phase 2 and Phase 3 in IPF, alongside emerging targets including galectin-3 from iTeos and LPA1 receptor antagonism from BMS. The IPF antifibrotic landscape has matured to the point where combination regimens pairing approved antifibrotics with novel mechanism partners are the primary clinical development question, as the plateau in FVC decline reduction achievable with single-mechanism therapy appears to limit monotherapy benefit beyond the 50-55% FVC decline reduction achieved by nintedanib and pirfenidone. Biomarker-guided patient selection using MMP-7, SPD, and CXCL13 serum markers is being validated in IPF trials to identify faster-progressing patients where antifibrotic combination regimens provide the greatest absolute benefit.

For related market intelligence, see the Respiratory Drug Market.